CSIMarket
 
Galera Therapeutics Inc   (GRTX)
Other Ticker:  
 
 
Price: $0.0420 $0.00 -8.696%
Day's High: $0.046 Week Perf: -7.28 %
Day's Low: $ 0.04 30 Day Perf: -16.83 %
Volume (M): 143 52 Wk High: $ 0.29
Volume (M$): $ 6 52 Wk Avg: $0.11
Open: $0.04 52 Wk Low: $0.02



 Market Capitalization (Millions $) 2
 Shares Outstanding (Millions) 54
 Employees 38
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -20
 Cash Flow (TTM) (Millions $) -16
 Capital Exp. (TTM) (Millions $) 0

Galera Therapeutics Inc
Galera Therapeutics Inc is a biotechnology company based in California, United States. The company focuses on developing and commercializing innovative therapeutics for the treatment of cancer and other diseases. Galera's main focus is on developing drugs that target the damaging effects of reactive oxygen species (ROS), which are produced in excess in cancer cells and other disease conditions.

The company's lead product candidate is known as GC4419, which is being developed as a treatment for the side effects of radiation therapy in cancer patients. Radiation therapy generates ROS, which can cause tissue damage and inflammation. GC4419 is designed to neutralize ROS and reduce the severity of side effects associated with radiation therapy, such as oral mucositis and radiation-induced fibrosis.

Galera Therapeutics is also exploring the potential of its technology in other therapeutic areas, including fibrosis and inflammation-related conditions. The company's approach involves using small molecules to target ROS and alleviate the damage caused by these molecules.

Overall, Galera Therapeutics aims to develop effective and safe therapies that improve the quality of life for patients with cancer and other diseases.


   Company Address: 45 Liberty Blvd, Suite 230 Malvern 19355 PA
   Company Phone Number: 725-1500   Stock Exchange / Ticker: GRTX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
AYTU   -5.49%    
KPTI        1.43% 
KZR   -0.96%    
MRSN        32.65% 
PIRS   -17.92%    
WVE   -5.82%    
• View Complete Report
   



Merger and Acquisition

Galera Therapeutics Bold Leap: Targeting Resistant Cancer with Revolutionary Trials,

Published Tue, Dec 31 2024 12:00 PM UTC

Galera Therapeutics Transforms Strategy with Focus on Anti-Cancer InnovationsIn a significant shift from its previous focus on toxicity reduction, Galera Therapeutics has announced a new development strategy centered on anti-cancer therapeutics. This transition comes at a crucial time for the company, as it ramps up clinical efforts by initiating three trials targeting pati...

Stock Market Announcement

Safeguarding Stockholder Interests: Galera Therapeutics' Proactive Defensive Strategy for Radiotherapy Advancements

Published Fri, May 3 2024 11:00 AM UTC

Unlocking the Potential of Radiotherapy: Galera Therapeutics Implements Stockholder Rights Agreement
In a bid to safeguard the interests of its stockholders, Galera Therapeutics, a biopharmaceutical company at the forefront of advancements in cancer radiotherapy, has recently announced the adoption of a limited duration stockholder rights agreement. With the potential to...

Galera Therapeutics Inc

Prominent Pharmaceutical Company Faces Corporate Challenges Amidst Third-Quarter Financial Downturn

roduction
The pharmaceutical industry has been closely following Galera Therapeutics Inc's third-quarter earnings report, providing valuable insights into the company's financial standing and its prospects for the near future. Despite reporting a significant operating shortfall, there are several positive developments that hint at a potential turnaround for this major player in the pharmaceutical preparations sector.
Operating Shortfall and Revenue Speculation
Galera Therapeutics Inc's third-quarter financial reporting showed an operating shortfall of $-13.396 million. While the company has not disclosed specific revenue figures for the July to September 30, 2023 period, this has left investors eagerly anticipating future business growth opportunities.

Galera Therapeutics Inc

Galera Therapeutics Inc Faces Potential Revenue Struggles, Reports Operating Loss and Significant Shortfall in Q2 2023

Galera Therapeutics Inc: A Potential Struggle for Revenue
Galera Therapeutics Inc, a lesser-known company in the Major Pharmaceutical Preparations sector, recently reported an operating loss of $-16.807 million for the second quarter of 2023. This marked a worsening from the operating loss of $-11.955 million in the same quarter of the previous year. However, what has caught the attention of market participants is the absence of revenue and the significant shortfall of $-20.712 million during the April to June 30, 2023 interval. This represents a considerable increase from the shortfall of $-14.558 million in the same period the previous year.
These financial results have raised concerns among investors and industry experts, who are speculating whether Galera Therapeutics and other companies in the Major Pharmaceutical Preparations sector may struggle to generate revenue. The lack of revenue along with increasing losses raises questions about the company's financial viability and ability to sustain its operations.

Galera Therapeutics Inc

Galera Therapeutics Inc Reports Surge in Operating Losses, Raises Concerns among Investors

Galera Therapeutics Inc (GRTX) has reported its financial performance for the January to March 31, 2023 reporting cycle, with stockholders not seeing any significant changes in revenue. However, the company's operating loss during the same period was reported to be $-13.881 million, a figure that investors are paying close attention to.
To put this into context, the operating loss for the first quarter of 2022 was $-13.154 million, and it is evident that there has not been significant progress in turning this deficit around. While certain choppy periods are expected during the process of developing prosperous revenue sources, it is still important to note that the operating loss for the fiscal interval ending March 31, 2023, has increased to $-17.710 million.










Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com